Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to a notification from FEDIOL and IMACE on fully refined soybean oil and fat pursuant to Article 6, paragraph 11 of Directive 2000/13/EC

,

doi:10.2903/j.efsa.2007.570

Cited by 2 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The levels of expression of PMI in the edible tissues (maize kernels) of the GMO crop were below the limits of detection of the ELISA employed which was 0.5 µg PMI protein/g tissue dry weight are not available in the published literature (European Food Safety Authority, 2009). This is of the order of 0.05 mg/Kg level similar to residual protein found in highly refined soybean oil (Rigby et al, 2011) for which an allergenic ingredient labelling exemption has been accepted (European Food Safety Authority, 2007). In vitro digestibility tests on the PMI show that it was readily digested (European Food Safety Authority, 2009).…”

Section: Gmos Expressing Phosphomannose Isomerasementioning

confidence: 90%

Novel strategies for predicting allergenicity: development of a ranking method and screening tools to assess the allergy risk of innovative proteins

Mills,

Orsenigo,

Salgado

et al. 2024

EFSA Supporting Publications

View full text Add to dashboard Cite

To protect individuals who already have or are at risk of developing immune‐mediated adverse reactions to food, novel foods and genetically modified organisms (GMOs) undergo an allergenicity risk assessment. There are shortcomings in this process that could be improved through use of well‐defined clinically relevant allergen molecules with different allergenic potential. The objective of this project was to develop novel strategies for predicting allergenicity of innovative/novel proteins that address this issue. We undertook a systematic review of allergen molecules in foods listed on Annex II of the Food Information for Consumers Regulation together with additional foods known to cause IgE‐mediated food allergies in at least one European region with a prevalence of 0.5%. Around 750 in‐scope papers were quality assessed to allow clinical relevance of allergen molecules to be ranked. The best characterised clinically relevant allergens were identified in peanut, hazelnut, cow's milk, fish and crustacean shellfish with data lacking for allergens from foods such as pecan, Macadamia, lupin and melon. Furthermore, an assessment of in silico tools allergenicity prediction found that, whilst many were able to correctly predict allergenicity, none were able to provide an output that could be linked to the clinical relevance. Building on these outcomes an approach for allergenicity risk assessment has been developed that brings together elements of exposure assessment, combining in silico, in vitro, and in vivo methods. Tools for assessment of risks of cross‐reactive allergies are more mature and only require refinement to improve the outputs to inform the allergenicity risk assessment process. However, as mechanisms underlying development of food allergy are not fully elucidated, and remain a matter of ongoing research, prediction of de novo sensitisation is uncertain.

show abstract

Section: Gmos Expressing Phosphomannose Isomerasementioning

confidence: 90%